Endologix (ELGX) Receives Media Sentiment Score of 0.17

News headlines about Endologix (NASDAQ:ELGX) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endologix earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 45.2518534651419 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Endologix (ELGX) traded up 3.99% during midday trading on Friday, hitting $5.21. 620,590 shares of the stock were exchanged. Endologix has a 12 month low of $4.08 and a 12 month high of $11.86. The stock’s market cap is $434.69 million. The firm’s 50-day moving average is $4.83 and its 200-day moving average is $5.17.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.08. The company had revenue of $48.60 million during the quarter, compared to the consensus estimate of $47.58 million. Endologix had a negative net margin of 33.55% and a negative return on equity of 68.19%. Endologix’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.20) EPS. Equities research analysts predict that Endologix will post ($0.62) earnings per share for the current year.

Several brokerages have commented on ELGX. ValuEngine lowered shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Oppenheimer Holdings, Inc. set a $5.00 price objective on shares of Endologix and gave the stock a “hold” rating in a report on Thursday, August 3rd. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a “hold” rating in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 target price for the company in a report on Monday, July 24th. Finally, Royal Bank Of Canada reiterated a “hold” rating and set a $5.00 target price on shares of Endologix in a report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating and eleven have issued a hold rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $6.28.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/27/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-endologix-elgx-share-price.html.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply